Loading stock data…
AMRN
$14.07+0.14 (+1.01%)
Market ClosedLast close May 1
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amarin Corporation plc in the Healthcare sector is trading at $14.07. The stock is currently 33% below its 52-week high of $20.90, remaining 9.2% below its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why AMRN maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.07
Potential Upside
5%
Whystock Fair Value$14.77
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$304.11M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.55%
Volume
Today's trading volume
301,570
Recent News
European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week
European equities traded in the US as American depositary receipts were trending marginally higher l
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning, gaini
Amarin Corp PLC (AMRN) Q1 2026 Earnings Call Highlights: Revenue Growth and Market Expansion ...
Amarin Corp PLC (AMRN) reports increased revenue and market share gains, while navigating cost pressures and competitive challenges.
Amarin Q1 Earnings Call Highlights
Amarin (NASDAQ:AMRN) reported first-quarter 2026 results that executives said showed continued momentum from late 2025, supported by a new operating model built around a cash-generating U.S. business and a partnered international strategy for Vascepa/Vazkepa. Management highlights restructuring pro
Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy
Improved margins and rising partner revenue highlight early impact of the company’s revised global model. Amarin Corporation plc (NASDAQ:AMRN) released its earnings report for the first quarter of 2026, showing revenue growth, significantly reduced operating expenses, and narrowing losses—developments that may signal early traction from its revamped global business strategy.